Loss of confidence in vaccines following media reports of infant deaths after hepatitis B vaccination in China.

Abstract

BACKGROUND:

China reduced hepatitis B virus (HBV) infection by 90% among children under 5 years old with safe and effective hepatitis B vaccines (HepB). In December 2013, this success was threatened by widespread media reports of infant deaths following HepB administration. Seventeen deaths and one case of anaphylactic shock following HBV vaccination had been reported.

METHODS:

We conducted a telephone survey to measure parental confidence in HepB in eleven provinces at four points in time; reviewed maternal HBV status and use of HepB for newborns in birth hospitals in eight provinces before and after the event; and monitored coverage with hepatitis B vaccine and other programme vaccines in ten provinces.

RESULTS:

HepB from the implicated company was suspended during the investigation, which showed that the deaths were not caused by HepB vaccination. Before the event, 85% respondents regarded domestic vaccines as safe, decreasing to 26.7% during the event. During the height of the crisis, 30% of parents reported being hesitant to vaccinate and 18.4% reported they would refuse HepB. Use of HepB in the monitored provinces decreased by 18.6%, from 53 653 doses the week before the event to 43 688 doses during the week that Biokangtai HepB was suspended. Use of HepB within the first day of life decreased by 10% among infants born to HBsAg-negative mothers, and by 6% among infants born to HBsAg-positive mothers. Vaccine refusal and HepB birth dose rates returned to baseline within 2 months; confidence increased, but remained below baseline.

CONCLUSIONS:

The HBV vaccine event resulted in the suspension of a safe vaccine, which was associated with a decline of parental confidence, and refusal of vaccination. Suspension of a vaccine can lead to loss of confidence that is difficult to recover. Timely and credible investigation, accompanied by proactive outreach to stakeholders and the media, may help mitigate negative impact of future coincidental adverse events following immunization.

• Authors: Wenzhou Yu, Dawei Liu, Jingshan Zheng, Yanmin Liu, Zhijie An, Lance Rodewald, Guomin Zhang, Qiru Su, Keli Li, Disha Xu, Fuzhen Wang, Ping Yuan, Wei Xia, Guijun Ning, Hui Zheng, Yaozhu Chu, Jian Cui, Mengjuan Duan, Lixin Hao, Yuqing Zhou, Zhenhua Wu, Xuan Zhang, Fuqiang Cui, Li Li, Huaqing Wang
• Journal: International journal of epidemiology (Int J Epidemiol) Vol. 45 Issue 2 Pg. 441-9 (04 2016) ISSN: 1464-3685 [Electronic] England
• PMID: 27174834 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © The Author 2016; all rights reserved. Published by Oxford University Press on behalf of the International Epidemiological Association.

Chemical References

• Hepatitis B Antibodies
• Hepatitis B Vaccines

Topics

• Adverse Drug Reaction Reporting Systems
• Cause of Death
• Child
• China (epidemiology)
• Drug-Related Side Effects and Adverse Reactions (ethnology, mortality)
• Female
• Hepatitis B (diagnosis, ethnology, prevention & control)
• Hepatitis B Antibodies (administration & dosage, adverse effects)
• Hepatitis B Vaccines (administration & dosage, adverse effects, immunology)
• Humans
• Immunization Programs
• Infant
• Infant Death
• Infant, Newborn
• Male
• Mass Media
• Surveys and Questionnaires
• Vaccination (statistics & numerical data, trends)